Demethylzeylasteral is primarily studied for its potential anti-cancer properties, particularly in inhibiting the growth and spread of tumor cells. It has shown activity in inducing apoptosis and suppressing metastasis in various cancer cell lines, including liver, breast, and colorectal cancers. The compound also exhibits anti-inflammatory effects by modulating key signaling pathways such as NF-κB and MAPK, making it a candidate for development in chronic inflammatory conditions. Additionally, it has been investigated for its ability to enhance the efficacy of conventional chemotherapeutic agents, suggesting a role as an adjuvant in cancer therapy. Research is ongoing to evaluate its pharmacokinetics and therapeutic potential in preclinical models.